Exploring the relationships between inflammatory response and coagulation cascade in inflammatory bowel disease

European Review for Medical and Pharmacological Sciences

Volumn 8, Issue 5, 2004, Pages 205-208

  Saibeni, S ^a   Spina, L ^a   Vecchi, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Coagulation; Inflammation; Inflammatory bowel disease; Thrombosis

Indexed keywords

BLOOD CLOTTING; DISEASE CONTROL; ENTERITIS; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; MEDICAL LITERATURE; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; THROMBOSIS;

EID: 10644290248     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Gabay C, Kushner B. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
2. Gillis S, Furie BC, Furie B. Interactions of neutrophils, platelets and the vessel during haemostasis and inflammation. Thromb Haemost 2001; 86: 746-756.
3. Johnson K, Aarden L, Choi Y, De Groot E, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
4. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation not fibrinolysis in humans. Thromb Haemost 1996; 76: 738-742.
5. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anti-coagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27: 3-9.
6. Devaraj S, Xu DY, Jialal I. C-Reactive Protein increases Plasminogen Activator Inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
7. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
8. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-Protein C-EPCR system. Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-1383.
9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
10. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145.
11. van Bodegraven AA. Haemostasis in inflammatory bowel diseases: clinical relevance. Scand J Gastroenterology 2003; 38 (Suppl 239): 51-62.
12. Hudson M, Chitolie A, Hutton R, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38: 733-737.
13. Webberly MJ, Hart M, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993; 34: 247-251.
14. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98: 112-117.
15. Souto JC, Martinez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-1889.
16. Saibeni S, Vecchi M, Valsecchi C, et al. Reduced free protein S levels in patients with inflammatory bowel disease. Prevalence, clinical relevance, and role of anti-protein S antibodies. Dig Dis Sci 2001; 46: 637-643.
17. Gris JC, Schved JF, Raffanel C, et al. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 1990; 63: 472-475.
18. Weber P, Husemann S, Vielhaber H, Zimmer KP, Nowak-Gottl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999; 28: 418-422.
19. Saibeni S, Bottasso B, Spina L, et al. Assessment of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) plasma levels in Inflammatory Bowel Diseases. Am J Gastroenterol 2004;99: 1966-1970.
20. Vecchi M, Cattaneo M, de Franchis R, Mannucci PM. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 1991; 21: 165-170.
21. Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn's disease. Blood Coag Fibrinol 1992; 3: 773-778.
22. Chamouard P, Grunebaum L, Wiesel ML, et al. Prothrombin fragment 1 + 2 and thrombin-antirthrombin III complex as markers of activation of blood coagulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 1183-1188.
23. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman H. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002, 14: 413-418.
24. Chiarantini E, Valanzano R, Liotta AA, et al. Persistence of haemostatic alterations in patients affected by Crohn's disease after bowel surgery. Thromb Res 1997; 87: 539-546.
25. Stadnicki A, Kloczko J, Nowk, Sierka E, Slivinski Z. Factor XIII subunits in relation to some other haemostatic parameters in ulcerative colitis. Am J Gastroenterol 1991; 86: 690-695.
26. Hudson M, Wakefield J, Hutton RA, et al. Factor XIIIa subunit and Crohn's disease. Gut 1993; 34: 35-39.
27. Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadell OB. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 637-643.
28. van Wersch JW, Houben P, Ruken J. Plaelet count, platelet function, coagulation activity and fibrinolysis in the cute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990; 28: 513-517.
29. Stevens TRJ, James JP, Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-506.
30. Boehme MWJ, Autschbach F, Zuna I, et al. Elevated serum levels and reduced immuno-histochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterol 1997; 113: 107-117.
31. Meucci G, Pareti F, Vecchi M, Saibeni S, Bressi C, de Franchis R. Serum von Willebrand Factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol 1999; 34: 287-290.
32. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-1062.
33. Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998; 352: 1742-1746.
34. Faioni EM, Ferrero S, Fontana G, et al. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 2004; 32: S266-S270.
35. Kjalke M, Monroe DM, Hoffman M, et al. Active site-inactivated factors VIIa, Xa, and IXa. inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost 1998; 80: 578-584.
36. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
37. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. BMJ 2002; 11: 173-177.
38. Solem CA, Loftus EV JR, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101.
39. Cattaneo M, Vecchi M, Zighetti ML, et al. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 1998; 80: 542-545.
40. Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procogualant profile and factor V Leiden. QJM 1997; 90: 183-188.